People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. 

The data were presented this week at both the 25th European Congress on Obesity (ECO 2018) in Vienna, Austria and the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018) in Baltimore, US. 

This retrospective effectiveness study investigated the impact of Saxenda® treatment in people with overweight and obesity across six weight management clinics in Canada. 

After six months, people treated with Saxenda® as an adjunct to diet and exercise achieved 7.1% weight loss from baseline, with 63.4% and 35.2% of people losing ≥5% and >10% of their body weight, respectively.

 Results from the real-world study were in line with those observed in the SCALE clinical trial programme. 

People treated with Saxenda® for at least six months also experienced improvements in cardiometabolic risk factors including blood glucose levels and systolic blood pressure. 

"Saxenda® is an important treatment option for people with obesity and reflects our commitment to help reduce the impact of obesity and improve the health of people living with the disease," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "It is great to see real-world evidence for Saxenda®, demonstrating that people are experiencing the benefits of Saxenda® seen in clinical trials." 

Saxenda® was generally well tolerated, with gastrointestinal side effects being the most frequently reported adverse events.